The PRoFESS trial: Future impact on secondary stroke prevention

Expert Review of Neurotherapeutics

Volumn 7, Issue 9, 2007, Pages 1085-1091

  Diener, Hans Christoph ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Aspirin; Blood pressure; Clopidogrel; Dipyridamole; Extended release; Placebo; Stroke; Stroke prevention; Stroke severity; Telmisartan; TIA; Vascular dementia

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TELMISARTAN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GYNECOLOGIC DISEASE; HEART INFARCTION; HEMATEMESIS; HEMATURIA; HUMAN; INTRAOCULAR HEMORRHAGE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; OCCLUSIVE CEREBROVASCULAR DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PURPURA; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; STROKE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; BENZIMIDAZOLES; BENZOATES; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; FORECASTING; HUMANS; INTERNATIONALITY; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TICLOPIDINE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 34548862350     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.9.1085     Document Type: Article

References (22)

1. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 284, 2901-2906 (2000).
2. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology 64(5), 817-820 (2005).
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarcton, and stroke in high risk patients. Br. Med. J. 524, 71-86 (2002).
4. Diener HC, Cuhna L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143, 1-13 (1996). •• First randomized trial demonstrating that the combination of extended-release (ER)-dipyridamole/aspirin is superior to aspirin monotherapy in the secondary prevention of stroke.
5. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 367, 1665-1673 (2006). •• Second randomized trial demonstrating that the combination of ERdipyridamole/ aspirin is superior to aspirin in prevention of vascular events after ischemic stroke.
6. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348, 1329-1339 (1996).
7. Diener H, Bogousslavsky J, Brass LM et al. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. Cerebrovasc. Dis. 17, 253-261 (2004). •• Randomized trial demonstrating that the combination of aspirin plus clopidogrel is not superior to clopidogrel monotherapy in secondary prevention of stroke, but carries a higher bleeding risk.
8. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354(16), 1706-1717 (2006). •• Randomized trial performed in primary and secondary prevention demonstrating that the combination of aspirin plus clopidogrel is not superior to aspirin monotherapy in the prevention of vascular events in patients with risk factors for stroke, myocardial infarction or peripheral arterial disease.
9. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl. 3), S483-S512 (2004).
10. Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomised trial. Br. Med. J. 324, 699-702 (2002).
11. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358, 1033-1041 (2001).
12. Schrader J, Luders S, Kulschewski A et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36(6), 1218-1226 (2005).
13. Schrader J, Lüders S, Kulschewski A et al. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34, 1699-1703 (2003).
14. Diener HC, Sacco R, Yusuf S. For the Steering Committee and PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens and telmisartan vs placebo in patients with strokes: the prevention regimen for effectively avoiding second strokes (PRoFESS) trial. Cerebrovasc. Dis. 23, 368-380 (2007).
15. Fisher LD, Gent M, Buller HR. Active control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin and placebo. Am. Heart J. 141, 26-32 (2001).
16. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62, 569-573 (2004).
17. Weimar C, Roth MP, Zillessen G et al. Complications following acute ischemic stroke. Eur. Neurol. 48, 133-140 (2002).
18. Thone-Reineke C, Zimmermann M, Neumann C et al. Are angiotensin receptor blockers neuroprotective? Curr. Hypertens. Rep. 6(4), 257-266 (2004).
19. Hankey GJ, Sudlow CLM, Dunbabin DW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomised trials. Stroke 31, 1779-1784 (2000).
20. Hardie K, Jamrozik K, Hankey GJ, Broadhurst RJ, Anderson C. Trends in five-year survival and risk of recurrent stroke after first-ever stroke in the Perth Community Stroke Study. Cerebrovasc. Dis. 19(3), 179-185 (2005).
21. Gent M, Blakely JA, Easton JD et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1(8649), 1215-1220 (1989).
22. Hass WK, Easton JD, Adams HP et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke. N. Engl. J. Med. 321, 501-507 (1989).